Supplementary Materials

The PDF file includes:

  • Fig. S1. Generation and characterization of an SCLC PDX model derived from isolated CTCs.
  • Fig. S2. NOTCH pathway marker changes in PDXs treated ex vivo with ORY-1001.
  • Fig. S3. Lack of NOTCH1 activation in NCI-H526 cells in response to ORY-1001.
  • Fig. S4. LSD1 binding and histone modification at REST locus in response to ORY-1001 in SCLC.
  • Fig. S5. Effects of ORY-1001 in nonadherent and adherent populations of FHSC04 cells.
  • Fig. S6. ORY-1001 efficacy and ASCL1 abundance in SCLC PDX model FHSC36.
  • Fig. S7. Toxicity analysis of in vivo responses to ORY-1001.
  • Fig. S8. Genomic alterations in PDX model FHSC04.
  • Fig. S9. Gene expression changes in FHSC04 in vivo in response to ORY-1001.
  • Legends for tables S1 to S10

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel file). ORY-1001 inhibits proliferation in a subset of SCLC cell lines.
  • Table S2 (Microsoft Excel file). DEseq2 analysis of differentially expressed transcripts in ORY-1001–treated SCLC cell lines.
  • Table S3 (Microsoft Excel file). Characteristics of the PDX models.
  • Table S4 (Microsoft Excel file). edgeR analysis of differentially expressed transcripts in ORY-1001–treated PDX SCLCs.
  • Table S5 (Microsoft Excel file). GO analysis of ORY-1001–treated PDXs.
  • Table S6 (Microsoft Excel file). edgeR analysis of ORY-1001–treated FHSC04 PDX tumors.
  • Table S7 (Microsoft Excel file). GO analysis of ORY-1001–treated FHSC04 PDX tumors.
  • Table S8 (Microsoft Excel file). shRNA sequences.
  • Table S9 (Microsoft Excel file). Primer sequences for qPCR.
  • Table S10 (Microsoft Excel file). Antibodies.